Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma

Allevato, Michael; Smith, Joshua D.; Brenner, Michael; Chinn, Steven B.

doi:10.1097/ppo.0000000000000671

Cited by 4 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These assays leverage ultrasensitive sequencing methods to detect cell-free HPV ctDNA shed from the primary tumor or metastatic deposits into circulation [19][20][21] . Numerous robust studies have shown promising sensitivity, specificity, and positive and negative predictive values of these assays for detecting locoregional and distant recurrences of HPV-related OPSCC [22][23][24][25] . We direct the reader to Kuhs et al for a contemporary review of published plasma HPV ctDNA test parameters [19] .…”

Section: Liquid Biomarkers For Surveillance Of Hpv-related Opsccmentioning

confidence: 99%

“…Plasma HPV ctDNA monitoring has shown robust statistical parameters for prediction and detection of locoregional and distant recurrences across several HPV-related OPSCC subgroups, including those with significant tobacco use history [20,21,25] . While no published study has been powered to examine this population specifically, preliminary results suggest that the kinetics of plasma HPV ctDNA levels accurately reflect the unique biology and disease activity of intermediate-risk HPV-related OPSCC [19] .…”

Section: A Biologically Distinct Populationmentioning

confidence: 99%

See 1 more Smart Citation

Consideration of liquid biomarkers for surveillance of HPV-related oropharyngeal cancer in veteran populations

Smith,

Spector,

Brenner

et al. 2024

J Cancer Metastasis Treat

Self Cite

View full text Add to dashboard Cite

The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) will continue to rise in the United States over the next several decades. Thus, efforts to reduce treatment intensity, mitigate long-term physical and psychological sequelae of treatment, and simplify surveillance regimens for patients with HPV-related OPSCC are critical. Liquid biomarkers, namely plasma circulating tumor HPV DNA (ctDNA), have shown considerable promise for improvements in these domains by guiding personalized and adaptive treatment de-escalation paradigms and predicting disease recurrence in the survivorship period. Preliminary reports suggest an even broader impact of plasma HPV ctDNA assays for HPV-related OPSCC surveillance beyond the mere detection of cancer recurrence and metastasis. For instance, such assays may reduce the need for costly imaging studies, alleviate the financial toxicities of survivorship care, and improve care access and patient satisfaction. Currently, veterans and underserved populations are disproportionately affected by the financial burden of cancer surveillance and survivorship care. These disparities negatively impact oncologic outcomes, healthcare access, and utilization, specifically among veterans with HPV-related OPSCC. As such, we posit that HPV ctDNA monitoring may be of unique benefit and impact in the surveillance period for these patients specifically. Herein, we provide a narrative review of the current literature supporting the formal clinical evaluation of HPV ctDNA monitoring in veterans with HPV-related OPSCC.

show abstract

Section: Liquid Biomarkers For Surveillance Of Hpv-related Opsccmentioning

confidence: 99%

Section: A Biologically Distinct Populationmentioning

confidence: 99%

Consideration of liquid biomarkers for surveillance of HPV-related oropharyngeal cancer in veteran populations

Smith,

Spector,

Brenner

et al. 2024

J Cancer Metastasis Treat

Self Cite

View full text Add to dashboard Cite

show abstract

“…These assays can use saliva, urine, or plasma-based biomarkers to improve diagnosis, treatment, and surveillance paradigms, but progress in developing robust and reliable liquid biopsy techniques for patients with HPV-negative HNSCC is more arduous. Nonetheless, preclinical and translational efforts are advancing liquid biopsy techniques for patients with HPV-negative tumors …”

mentioning

confidence: 99%

Liquid Biopsies for Head and Neck Cancers—Any Hope for Human Papillomavirus–Negative Disease?

Smith,

Brenner,

Chinn

2024

JAMA Otolaryngol Head Neck Surg

Self Cite

View full text Add to dashboard Cite

To the Editor Ferrandino et al 1 report clinical performance of plasma tumor tissue-modified viral (TTMV)-human papillomavirus (HPV) DNA in diagnosis and surveillance of HPVassociated oropharyngeal squamous cell carcinoma (OPSCC). The findings highlight the promise of liquid biopsies for improving patient care and the uncertainties around how to integrate these assays with imaging, clinical examinations, and conventional biopsy. 2 The variable time points for plasma TTMV-HPV DNA monitoring limited estimates of lead time detection, suggesting an opportunity for further standardizing timing of liquid biopsy testing protocols. A key question is whether liquid biopsies have a role in HPV-negative OPSCC.Whereas plasma TTMV-HPV DNA assays detect viral DNA shed from the primary tumor or metastatic deposits, HPVnegative head and neck squamous cell carcinoma (HNSCC) lacks this viral fingerprint. Biomarkers for HPV-negative HNSCC are thus more nuanced, relying on detection of genomic and/or proteomic signatures of the parent tumor. These assays can use saliva, urine, or plasma-based biomarkers to improve diagnosis, treatment, and surveillance paradigms, but progress in developing robust and reliable liquid biopsy techniques for patients with HPV-negative HNSCC is more arduous. Nonetheless, preclinical and translational efforts are advancing liquid biopsy techniques for patients with HPV-negative tumors. 3 Recently, plasma tumor-derived extracellular vesicles (TDEVs), also known as exosomes, have emerged as a promising alternative to the circulating tumor DNA techniques. TDEVs are small (30 nm-200 nm), lipid-bilayer bound particles that are constitutively released by malignant cells harboring diverse DNA, RNA, and protein cargo. These particles are abundant in saliva, urine, and plasma of patients with HPVnegative HNSCC and can be readily isolated before, during, and after treatment. TDEVs have been studied in multiple cancers, including HPV-negative HNSCC. 4 Plasma TDEV kinetics and protein cargo (eg, surface programmed cell death ligand 1 [PD-L1] expression) can predict disease recurrence and treatment response in certain HPV-negative HNSCC populations. 5 The study by Ferrandino et al 1 underscores the need for further investigation of liquid biopsy, encompassing the implications for de-escalating therapy and improving patient out-

show abstract

Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future

Chen

2024

Oral Oncology

View full text Add to dashboard Cite

Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma

Cited by 4 publications

References 89 publications

Consideration of liquid biomarkers for surveillance of HPV-related oropharyngeal cancer in veteran populations

Consideration of liquid biomarkers for surveillance of HPV-related oropharyngeal cancer in veteran populations

Liquid Biopsies for Head and Neck Cancers—Any Hope for Human Papillomavirus–Negative Disease?

Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future

Contact Info

Product

Resources

About